FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
|Articles|September 16, 2021
Pharmacy Clinical Pearl of the Day: Multiple Sclerosis
Author(s)Saro Arakelians, PharmD
In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers, causing deterioration of the nerves.
Advertisement
Clinical Pearl of the Day: Multiple Sclerosis
Multiple sclerosis (MS) is a disease of the brain and spinal cord.
Explanation:
- In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers, causing deterioration of the nerves.
- Symptoms of MS include numbness, weakness, tremor, lack of coordination, blurry vision, double vision, slurred speech, fatigues, dizziness, tingling, and problems with bowel and bladder function.
- Diagnosis could include blood test, spinal tap, MRI, and an evoked potential test.
- Treatment options may include Interferon beta, Copaxone, Gilenya, Tecfidera, Vumerity, Aubagio, Mayzent, Mavenclad, Ocrevus, Tysarbi, Lemtrada, and physical therapy.
References
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.
In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
Pharmacists can explain the evidence supporting the intramuscular injection, address specific concerns, and help families understand what is known—and what is not known—about oral vitamin K.
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
Pneumonic Plague: Symptoms, Antibiotics, and Current US Risk
3
Inside the New Consensus Recommendations for Acute Stroke Care
4
The Coding Gap Nobody Prices In: Why New Specialty Drugs Launch Reimbursement-Blind
5